Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0268596 (
EMA
)
2,520
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
NHERF1
/EBP50, an adaptor protein required for epithelial morphogenesis, has been implicated in the progression of various human malignancies.
NHERF1
-deficient mice have intestinal brush border structural defects and we report here that they also have disorganized ependymal cilia with development of non-obstructive hydrocephalus. Examination of mouse and human brain tissues revealed highest
NHERF1
expression at the apical plasma membrane of ependymal cells. In ependymal tumors,
NHERF1
expression was retained in polarized membrane structures, such as microlumens, rosettes and canals, where it co-localized with some of its ligands, such as moesin and PTEN. Analysis of a comprehensive panel of 113 tumors showed robust
NHERF1
labeling of microlumens in 100% of ependymomas, subependymomas, and pediatric anaplastic ependymomas, and in 67% of adult anaplastic ependymomas.
NHERF1
staining was present in 35% of ependymoma cases that lacked reactivity for
EMA
, the routine immunohistochemical marker used for ependymoma diagnosis.
NHERF1
labeling of microlumens was either absent or rarely seen in other types of brain tumors analyzed, denoting
NHERF1
as a reliable diagnostic marker of ependymal tumors. Anaplastic foci and a subset of adult anaplastic ependymomas showed complete absence of
NHERF1
-labeled polarity structures, consistent with a loss of differentiation in these aggressive tumors. These data highlight a role for
NHERF1
in ependymal morphogenesis with direct application to the diagnosis of ependymal tumors.
...
PMID:NHERF1/EBP50 is an organizer of polarity structures and a diagnostic marker in ependymoma. 2577 75